Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

ClinicalTrials.gov ID: NCT02184195

Public ClinicalTrials.gov record NCT02184195. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:00 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Study identification

NCT ID: NCT02184195
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 154 participants

Conditions and interventions

Conditions

Interventions

Olaparib Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 16, 2014 (Actual)
Primary completion: Jan 15, 2019 (Actual)
Completion: Jan 27, 2023 (Actual)
Last update posted: Sep 13, 2023

2014 – 2023

United States locations

U.S. sites: 20
U.S. states: 14
U.S. cities: 17

Facility	City	State	ZIP	Site status
Research Site	Gilbert	Arizona	85234	—
Research Site	Orange	California	92868	—
Research Site	Stanford	California	94305-5720	—
Research Site	Aurora	Colorado	80045	—
Research Site	New Haven	Connecticut	06510	—
Research Site	Boca Raton	Florida	33486	—
Research Site	Miami	Florida	33136	—
Research Site	Chicago	Illinois	60637	—
Research Site	Baltimore	Maryland	21287	—
Research Site	Boston	Massachusetts	02215	—
Research Site	St Louis	Missouri	63110	—
Research Site	Commack	New York	11725	—
Research Site	New York	New York	10016	—
Research Site	New York	New York	10022	—
Research Site	New York	New York	10032	—
Research Site	New York	New York	10065	—
Research Site	Columbus	Ohio	43210	—
Research Site	Philadelphia	Pennsylvania	19111	—
Research Site	Houston	Texas	77030	—
Research Site	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02184195, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 13, 2023 · Synced Nov 3, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02184195 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →